PE Consortium and Ventana Signs Agreement for Collaborative Venture
26 Août 2009 - 3:08PM
Marketwired
Ventana Biotech Inc ("Ventana") (PINK SHEETS: VNTA), a
biotechnology company that is developing a ground breaking
appetite-suppressing chewing gum today announced it has signed is
in collaboration negotiations with PE Consortium Ltd, a company
that focuses on the research and development and outsourcing of new
obesity treating drug targets. The two companies have signed a
Letter of Intent with a view to sign a collaboration agreement.
The two companies have formalized their desire to collaborate in
a recent Letter of Intent, and are presently preparing the
contractual details of their collaboration. They plan to primarily
focus on the sourcing of obesity treatments, but are open to future
expansion to other therapeutic areas as well.
PE Consortium Ltd's strength lies in identifying and acquiring
promising obesity treatments through the relationships it has built
with academic research institutions around the world, their
expertise and experience in that area would be a welcome
enhancement to Ventana's current sourcing efforts.
About Ventana Biotech Inc
Ventana is positioning itself as the leading bioscience company
in the development and commercial licensure of novel therapeutic
anti-obesity drug treatment. The company leverages cutting-edge
research collaborations to achieve breakthroughs in innovative
anti-obesity treatments, and then licenses these patented drug
product candidates to Big Pharmaceutical and Biotechnology
companies.
FORWARD-LOOKING STATEMENTS:
Statements about Ventana's future expectations and all other
statements in this press release other than historical facts are
"forward-looking statements" within the meaning of section 27A of
the Securities Act of 1933, Section 21E of the Securities Exchange
Act of 1934, and as the term is defined in the Private Litigation
Reform Act of 1995. Ventana's actual results could differ
materially from expected results. Ventana does not undertake any
obligation to update forward-looking statements to reflect
subsequently occurring events or circumstances. Should events occur
which materially affect any comments made within this objective,
Ventana will appropriately inform the public.
For more information about Ventana Biotech Inc please contact
investor@ventanabiotech.com
Contacts: Ventana Biotech Inc Janne Christensen, CEO BCB 1
Bachstrasse Butschwil CH-9606 Switzerland Mobile: +44 7930 732
426
VetaNova (CE) (USOTC:VTNA)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025
VetaNova (CE) (USOTC:VTNA)
Graphique Historique de l'Action
De Jan 2024 à Jan 2025
Real-Time news about VetaNova Inc (CE) (OTCMarkets): 0 recent articles
Plus d'articles sur Ventana Biotech Inc